810668-37-2

Usage

Uses

Used in Pharmaceutical Industry:
Resolvin D2 is used as an anti-inflammatory agent for its ability to dampen excessive neutrophil trafficking to sites of inflammation, reduce leukocyte-endothelial interactions, and decrease production of pro-inflammatory cytokines. Its role in promoting the resolution of inflammatory responses makes it a promising candidate for the development of therapeutic agents targeting various inflammatory conditions.
Used in Biomedical Research:
Resolvin D2 is used as a research tool for studying the mechanisms underlying the resolution of inflammation and the role of specialized pro-resolving mediators in modulating immune responses. It aids in understanding the complex interactions between immune cells and the development of novel therapeutic strategies for treating inflammatory disorders.
Used in Drug Development:
Resolvin D2 is used as a lead compound for the development of new drugs targeting inflammatory conditions. Its potent anti-inflammatory properties and ability to promote the resolution of inflammation make it a valuable starting point for designing and optimizing drug candidates with improved efficacy and safety profiles.
Used in Nutritional Supplements:
Resolvin D2 can be used as a nutritional supplement to support a healthy inflammatory response and promote overall well-being. Its role in reducing excessive neutrophil trafficking and decreasing pro-inflammatory cytokine production may contribute to maintaining a balanced immune system and supporting the body's natural healing processes.

Upstream product

• 6089-09-4 4-pentynoic acid 
• 810668-53-2 (4Z,7S,8E,10Z,12E,14E,16R,17S,19Z)-methyl 7,16,17-trihydroxydocosa-4,8,10,12,14,19-hexaenoate 
• 105499-53-4 [(4R,5S)-2,2-Dimethyl-5-((Z)-pent-2-enyl)-[1,3]dioxolan-4-yl]-methanol 
• 86795-44-0 3,4-O-isopropylidene-2-deoxy-D-ribose 
• 810668-44-1 (S)-7,8-Bis-triethylsilanyloxy-oct-4-ynoic acid methyl ester 
• 810668-42-9 (S)-7,8-Dihydroxy-oct-4-ynoic acid methyl ester 
• 810668-40-7 oct-7-en-4-ynoic acid methyl ester 
• 129646-09-9 (4S,5S)-2,2-Dimethyl-5-((Z)-pent-2-enyl)-[1,3]dioxolane-4-carbaldehyde 
• 810668-50-9 (4Z,8E,12E,14E)-(S)-15-[(4R,5S)-2,2-Dimethyl-5-((Z)-pent-2-enyl)-[1,3]dioxolan-4-yl]-7-triethylsilanyloxy-pentadeca-4,8,12,14-tetraen-10-ynoic acid methyl ester 
• 810668-51-0 (S,4Z,8E,12E,14E)-methyl 15-((4R,5S)-2,2-dimethyl-5-((Z)-pent-2-en-1-yl)-1,3-dioxolan-4-yl)-7-hydroxypentadeca-4,8,12,14-tetraen-10-ynoate 
• 810668-52-1 (4Z,7S,8E,12E,14E,16R,17S,19Z)-methyl 7,16,17-trihydroxydocosa-4,8,12,14,19-pentaen-10-ynoate 
• 810668-45-2 (Z)-(S)-7,8-Bis-triethylsilanyloxy-oct-4-enoic acid methyl ester 

Relevant academic research and scientific papers

First total synthesis of 7(S),16(R),17(S)-Resolvin D2, a potent anti-inflammatory lipid mediator

A total synthesis of a biological highly active lipid mediator derived from docosahexaenoic acid is described. The first total synthesis of 7(S),16(R),17(S)-Resolvin D2, a lipid mediator derived from docosahexaenoic acid, has been achieved. The key features of our synthetic strategy encompass a Co-salen hydrolytic kinetic resolution of a terminal epoxide combined with a chiral pool strategy.

Total synthesis of the endogenous inflammation resolving lipid resolvin D2 using a common lynchpin

The total synthesis of the endogenous inflammation resolving eicosanoid resolvin D2 (1) is described. The key steps involved a Wittig reaction between aldehyde 5 and the ylide derived from phosphonium salt 6 to give enyne 17 and condensation of the same ylide with aldehyde 7 to afford enyne 11. Desilylation of 11 followed by hydrozirconation and iodination gave the vinyl iodide 4 and Sonogashira coupling between this compound and enyne 3 provided alkyne 18. Acetonide deprotection, partial reduction and ester hydrolysis then gave resolvin D2 (1).

COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION

The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

USE OF DOCOSATRIENES, RESOLVINS AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA

The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful ;isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.